Indications
Riltrava Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).
Composition
- Active substance
- Budesonide, formoterol fumarate dihydrate, glycopyrronium bromide
- International name (INN)
- formoterol fumarate dihydrate;glycopyrronium;budesonide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Riltrava Aerosphere
- Active substance
- Budesonide, formoterol fumarate dihydrate, glycopyrronium bromide
- ATC code
- R03AL11